XML 41 R29.htm IDEA: XBRL DOCUMENT v3.22.4
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Research And Development Cost $ 1,113,500 $ 375,032
Cash 1,182,412  
Other assets 34,742  
Intangible asset 1,028,114  
Revenues from sale of treatability services 63,501  
Revenues from sales $ 2,952,020  
Warrants [Member]    
Antidilutive Excluded from Computation of Earnings Per Share, Amount 12,752,000 1,250,000